News

 

The contribution of SCN1A mutations to the manifestation of SMEI has been firmly established. It has further been shown that approximately 15% of all SMEI cases caused by SCN1A mutations represents large deletions. To optimise our testing panel Amplexa now launches a MLPA based analyses for major deletions and duplications of SCN1A.

More
 

Amplexa Genetics is collaborating in a study aimed to search for susceptibility genes in generalized idiopathic epilepsy in the population of the Faroe Island. Other participants are The Danish Epilepsy Centre, The National Hospital on the Faroe Islands and the Copenhagen University Hospital. The project has obtained economical support from The Faroese Research Counsil and the Lundbeck Foundation.

More